Abstract 205P
Background
CTCF-binding site (BS) occupancy is plastic, tissue specific and altered in cancer. This principle underlies some fragmentomics methods. We hypothesized that ChIP-Seq of plasma CTCF-cfDNA might identify CTCF-BSs selectively occupied in cancer and that, having removed all nucleosomes or other non-CTCF bound cfDNA by CTCF immunoprecipitation (IP), the presence of cfDNA fragments corresponding to sites selectively CTCF occupied in cancer may be tested for by PCR. We now report a novel liquid biopsy method, and initial results, based on this principle.
Methods
(i) Identification of CTCF-BSs selectively occupied in cancer samples. Plasma samples were collected from healthy volunteers (n=5), and patients with inflammatory conditions (n=5) or cancer (n=5). IP was performed using anti-CTCF coated magnetic beads and immunoprecipitated cfDNA was extracted, amplified and sequenced on an Illumina platform. (ii) We developed specific qPCR assays for 10 CTCF-BS sequences that we observed to be preferentially bound in the plasma of cancer patients vs either inflammatory conditions or healthy subjects. The panel of qPCR assays was tested on CTCF associated cfDNA isolated from plasma samples (1ml) obtained from patients diagnosed with a variety of common solid cancer diseases (n=48).
Results
We observed that specific CTCF IP resulted in isolation of cfDNA fragments with a frequency peak in the 30-80bp range that was not present in negative controls (mouse-IgG). These short cfDNA fragments included previously described CTCF binding sites. Moreover, CTCF binding sites were not randomly distributed on cfDNA fragments but located at the centre of each fragment. Among the CTCF occupied binding sites observed, we identified 29 sites that were significantly differentially bound in cancer. We observed highly sensitive and specific qPCR test results for a number of common solid cancer diseases including high sensitivity at disease stage I and II.
Conclusions
This is the first demonstration of IP of plasma CTCF-cfDNA. IP followed by multiplex PCR may form the basis of a rapid, low cost liquid biopsy method that obviates expensive library preparation and NGS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Belgian Volition.
Funding
Belgian Volition.
Disclosure
D. Pamart, J-V. Turatsinze, B. Cuvelier, J-V. Turatsinze: Financial Interests, Personal, Full or part-time Employment: Belgian Volition. M. Herzog: Financial Interests, Personal, Full or part-time Employment: Belgian Volition; Financial Interests, Personal, Stocks/Shares: VolitionRx. J. Micallef: Financial Interests, Personal, Officer, Chief Scientific Officer: VolitionRx Ltd; Financial Interests, Personal, Stocks/Shares: VolitionRx Ltd.
Resources from the same session
207P - Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Presenter: Maged Khalil
Session: Poster session 01
208P - Identification of BCOR mutation as a novel predictor of immunotherapy efficacy in gastrointestinal tumors
Presenter: Wuping Wang
Session: Poster session 01
209P - Molecular atlas of copy number variation(CNV) in lung cancer with brain metastases
Presenter: Xianfeng Zhang
Session: Poster session 01
210P - Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery
Presenter: Andrea Riccardo Filippi
Session: Poster session 01
211P - Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
Presenter: Evgeny Imyanitov
Session: Poster session 01
212P - Extracellular vesicle miRNA as effective biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade
Presenter: Si Sun
Session: Poster session 01
213P - Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway
Presenter: Hege Russnes
Session: Poster session 01
214P - PESSA: A shiny app for pathway enrichment score-based survival analysis in cancer
Presenter: Ying Shi
Session: Poster session 01
215P - Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
Presenter: Camila Xavier
Session: Poster session 01
216P - PTCH1 mutation as a potential predictor of immune checkpoint inhibitors in gastrointestinal cancer
Presenter: Yang Tang
Session: Poster session 01